MedKoo Cat#: 522390 | Name: GW627368X
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

GW627368X is a novel, potent and selective competitive antagonist of prostanoid EP4 receptors with additional human TP receptor affinity. Oral administration of GW627368X showed significant tumor regression characterized by tumor reduction and induction of apoptosis. Reduction in prostaglandin E2 synthesis also led to reduced level of VEGF in plasma. GW627368X will be a valuable tool to explore the role of the prostanoid EP4 receptor in many physiological and pathological settings.

Chemical Structure

GW627368X
GW627368X
CAS#439288-66-1

Theoretical Analysis

MedKoo Cat#: 522390

Name: GW627368X

CAS#: 439288-66-1

Chemical Formula: C30H28N2O6S

Exact Mass: 544.1668

Molecular Weight: 544.62

Elemental Analysis: C, 66.16; H, 5.18; N, 5.14; O, 17.63; S, 5.89

Price and Availability

Size Price Availability Quantity
5mg USD 90.00 Ready to ship
10mg USD 150.00 Ready to ship
25mg USD 250.00 Ready to ship
50mg USD 450.00 Ready to ship
100mg USD 750.00 Ready to ship
200mg USD 1,350.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
GW627368X; GW 627368X; GW-627368X; GW627368; GW 627368; GW-627368.
IUPAC/Chemical Name
2-(4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl)-N-(phenylsulfonyl)acetamide
InChi Key
XREWXJVMYAXCJV-UHFFFAOYSA-N
InChi Code
InChI=1S/C30H28N2O6S/c1-3-37-28-23-12-8-9-13-24(23)29(38-4-2)27-25(28)19-32(30(27)34)21-16-14-20(15-17-21)18-26(33)31-39(35,36)22-10-6-5-7-11-22/h5-17H,3-4,18-19H2,1-2H3,(H,31,33)
SMILES Code
O=C(NS(=O)(C1=CC=CC=C1)=O)CC2=CC=C(N(CC3=C4C(OCC)=C(C=CC=C5)C5=C3OCC)C4=O)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
GW627368 (GW627368X) is a novel, potent and selective competitive antagonist of prostanoid EP4 receptor with additional human TP receptor affinity, with pKi values of 7.0 and 6.8 for human prostanoid EP4 and TP receptors respectively.
In vitro activity:
GW627368X inhibits growth in cervical cancer cells by inducing apoptosis was indicated by morphological studies using DAPI/Rhodamine phalloidin staining (Figure 2a). Typical changes in cell morphology including cell shrinkage, disruption of actin filaments, nuclear fragmentation and apoptososme formation was observed. Apoptotic cell death was further confirmed by a timedependent increase in terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)-positive green nuclei (Figure 2b). Reference: Cell Death Dis. 2016 Mar 24;7(3):e2154. https://pubmed.ncbi.nlm.nih.gov/27010855/
In vivo activity:
To evaluate the effect of GW627368X on signaling within tumor environment, the expression profile of various phosphorylated and non-phosphorylated proteins were studied by immunohistochemistry and western blotting (Fig. 3). A significant decrease in phosphorylation level of signaling mediators like EGFR, VEGFR, Akt, MAPK etc was observed with increase in dose of the drug while the total proteins seemed to remain equal in all the sets (Fig. 3D). In addition, highly significant down regulation of COX-2 and EP4 was observed (Fig. 3A). The key player of the cascade, Prostaglandin E2 in plasma and tissue was quantified using enzyme immune assay. The plasma and tissue levels of prostaglandin E-2 drastically reduced from 720.7 ± 11.11pg/ml in control group to 200 ± 0.7076 pg/g in high treatment group vs. 248.8 ± 16.40 pg/ml in normal mice (Fig. 3C). The effect was highly significant. Reference: Cancer Biol Ther. 2015;16(6):922-32. https://pubmed.ncbi.nlm.nih.gov/25894216/
Solvent mg/mL mM
Solubility
DMF 30.0 55.08
DMF:PBS (pH 7.2) (1:2) 0.3 0.55
DMSO 54.8 100.66
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 544.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Parida S, Pal I, Parekh A, Thakur B, Bharti R, Das S, Mandal M. GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling. Cell Death Dis. 2016 Mar 24;7(3):e2154. doi: 10.1038/cddis.2016.61. PMID: 27010855; PMCID: PMC4823960. 2. Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, Brown J, Wise A, Chowdhury J, Pritchard S, Coote J, Noel LS, Kenakin T, Burns-Kurtis CL, Morrison V, Gray DW, Giles H. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2Hbenzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol. 2006 Jun;148(3):326-39. doi: 10.1038/sj.bjp.0706726. PMID: 16604093; PMCID: PMC1751567 3. Parida S, Parekh A, Dey G, Ghosh SC, Mandal M. Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model. Cancer Biol Ther. 2015;16(6):922-32. doi: 10.1080/15384047.2015.1040953. Epub 2015 Apr 20. PMID: 25894216; PMCID: PMC4623220.
In vitro protocol:
1. Parida S, Pal I, Parekh A, Thakur B, Bharti R, Das S, Mandal M. GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling. Cell Death Dis. 2016 Mar 24;7(3):e2154. doi: 10.1038/cddis.2016.61. PMID: 27010855; PMCID: PMC4823960. 2. Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, Brown J, Wise A, Chowdhury J, Pritchard S, Coote J, Noel LS, Kenakin T, Burns-Kurtis CL, Morrison V, Gray DW, Giles H. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2Hbenzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol. 2006 Jun;148(3):326-39. doi: 10.1038/sj.bjp.0706726. PMID: 16604093; PMCID: PMC1751567
In vivo protocol:
1. Parida S, Parekh A, Dey G, Ghosh SC, Mandal M. Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model. Cancer Biol Ther. 2015;16(6):922-32. doi: 10.1080/15384047.2015.1040953. Epub 2015 Apr 20. PMID: 25894216; PMCID: PMC4623220. Product data sheet MedKoo Biosciences || http://www.medkoo.com || sales@medkoo.com 2500 Gateway Centre Blvd Suite 400, Morrisville, NC27560, USA. Tel: 919-636-5577, Fax: 919-980-4831 2. Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, Brown J, Wise A, Chowdhury J, Pritchard S, Coote J, Noel LS, Kenakin T, Burns-Kurtis CL, Morrison V, Gray DW, Giles H. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2Hbenzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol. 2006 Jun;148(3):326-39. doi: 10.1038/sj.bjp.0706726. PMID: 16604093; PMCID: PMC1751567
1: Parida S, Parekh A, Dey G, Ghosh SC, Mandal M. Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model. Cancer Biol Ther. 2015;16(6):922-32. doi: 10.1080/15384047.2015.1040953. Epub 2015 Apr 20. PubMed PMID: 25894216. 2: Wilson RJ, Giblin GM, Roomans S, Rhodes SA, Cartwright KA, Shield VJ, Brown J, Wise A, Chowdhury J, Pritchard S, Coote J, Noel LS, Kenakin T, Burns-Kurtis CL, Morrison V, Gray DW, Giles H. GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol. 2006 Jun;148(3):326-39. PubMed PMID: 16604093; PubMed Central PMCID: PMC1751567.